anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Specialized receptors (RAGE, Galectin 3...) bind AGE. The binding to the receptor causes the formation of free radicals, which have a deleterious effect because they are powerful oxidizing agents, but also play the role of intracellular messenger, altering the cell functions.

This role is especially true at the level of endothelial cells as the attachment of AGE to RAGE receptor causes an increase in vascular permeability. AGE binding to endothelium RAGE and to monocytes-macrophages, led to the production of cytokines, growth factors, to the expression of adhesion molecules, and the production of procoagulant activity. Increased permeability, facilitation of leukocyte migration, the production of reactive oxygen species, cytokines and VEGF suggest that the AGE could be an element of a cascade of reactions responsible for the diabetic angiopathy and vascular damages observed during aging and chronic renal failure. Recently, It's been proposed that balanced diets can limit the deleterious effect of AGE. For these reasons, the interest in preventive approaches complementary or alternative to cholesterol reduction should be one of the main objectives of cardiovascular research in the years to come. Already in the '70s the very low incidence of atherosclerotic diseases in Mediterranean countries (Greece and Southern Italy) and the importance of the "dietary factor" in such protection were noticed. Diets for people in these countries are, among other components, very rich in oleic acid, the main constituent of olive oil, with about 29% of daily caloric intake derived from monounsaturated fatty acids. Aim of this trial is to estimate the effect of a Low Glycemic Index Mediterranean Diet on AGE products.
Many patients infected with the SARS-CoV-2 virus (COVID-19) continue to experience symptoms for weeks to years as sequelae of the initial infection, referred to as "Long COVID". Although many studies have described the incidence and symptomatology of Long COVID, there are little data reporting the potential burden of Long COVID on surgical departments. A previously constructed database of survey respondents who tested positive for COVID-19 was queried, identifying patients reporting experiencing symptoms consistent with Long COVID. Additional chart review determined whether respondents had a surgical or non-routine invasive procedure on or following the date of survey completion. Outcomes from surgeries on patients reporting Long COVID symptoms were compared to those from asymptomatic patients. A total of 17.4% of respondents had surgery or a non-routine invasive procedure in the study period. A total of 48.8% of these patients reported experiencing symptoms consistent with Long COVID. No statistically significant differences in surgical outcomes were found between groups. The results of this analysis demonstrate that Long COVID does not appear to have created a significant burden of surgical disease processes on the healthcare system despite the wide range of chronic symptoms and increased healthcare utilization by this population. This knowledge can help guide surgical operational resource allocation as a result of the pandemic and its longer-term sequelae.
The invention discloses an intelligent medicine box which is characterized in that a monocular camera is based on, a deep learning face recognition network is adopted, key feature points of faces of users are detected, different users are recognized, a designated medicine storage bin is positioned and popped out by controlling a motor, and the medicine taking quantity is prompted. The invention can record the medicine information and the character information and check the medicine use log through the small program terminal. When the user takes the medicine at the time of taking the medicine or does not take the medicine in time within the set time, the user or family members can be reminded through the small program terminal. The intelligent medicine box has the advantages that the voice and light interaction function is added, complicated key pressing or touch operation is eliminated, humanized voice interaction medicine taking is realized, and users at all ages can easily use the medicine box. The invention can be applied to family environment, outdoor or hospital, etc., to shorten the time for taking medicine from patients and reduce the consumption of medical resources, thereby improving the medical efficiency. The intelligent medicine chest reduces the contact of personnel and provides convenience.
Risk Summary Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no evidence of embryo-fetal toxicity was observed with oral administration of fenofibrate in rats and rabbits during organogenesis at doses less than or equivalent to the maximum recommended clinical dose of 160 mg daily, based on body surface area (mg/m2). Adverse reproductive outcomes occurred at higher doses in the presence of maternal toxicity (see Data). Fenofibrate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

In pregnant rats given oral dietary doses of 14, 127, and 361 mg/kg/day from gestation day 6-15 during the period of organogenesis, no adverse developmental findings were observed at 14 mg/kg/day (less than the clinical exposure at the maximum recommended human dose [MRHD] of 300 mg fenofibrate daily, equivalent to 160 mg fenofibrate tablets daily, based on body surface area comparisons). Increased fetal skeletal malformations were observed at maternally toxic doses (361 mg/kg/day, corresponding to 12 times the clinical exposure at the MRHD) that significantly suppressed maternal body weight gain.

pregnant rabbits given oral gavage doses of 15, 150, and 300 mg/kg/day from gestation day 6-18 during the period of organogenesis and allowed to deliver, no adverse developmental findings were observed at 15 mg/kg/day (a dose that approximates the clinical exposure at the MRHD, based on body surface area comparisons). Aborted litters were observed at maternally toxic doses (>150 mg/kg/day, corresponding to > 10 times the clinical exposure at the MRHD) that suppressed maternal body weight gain.

In pregnant rats given oral dietary doses of 15, 75, and 300 mg/kg/day from gestation day 15 through lactation day 21 (weaning), no adverse developmental effects were observed at 15 mg/kg/day (less than the clinical exposure at the MRHD, based on body surface area comparisons), despite maternal toxicity (decreased weight gain). Post-implantation loss was observed at >75 mg/kg/day (> 2 times the clinical exposure at the MRHD) in the presence of maternal toxicity (decreased weight gain). Decreased pup survival was noted at 300 mg/kg/day (10 times the clinical exposure at the MRHD), which was associated with decreased maternal body weight gain/maternal neglet.
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to novel derivative of 2-(3H)-oxazolone of the formula (I)   where R 1  means alkyl group or group -NR 4 R 5  where each R 4  and R 5  means independently hydrogen atom, alkyl or benzyl group; R 2  means naphthyl, unsubstituted phenyl group or phenyl group substituted with from 1 to 3 halogen atoms, alkyl group, hydroxy-, alkoxy- or trifluoromethyl-group; R 3  means hydrogen atom or alkyl group. Method of synthesis of compound of the formula (I) involves interaction of carbamate of the formula (V)   with anhydrous acetic acid or interaction of mercapto-derivative of the formula (VIII)   with oxidizing agent, or interaction of chlorosulfonyl of the formula (XI)   with amine of the formula R 4 -NH-R 5 , or debenzylation of compound of the formula (IX)  . Invention relates also to pharmaceutical composition showing anti-inflammatory effect and comprising compound of the formula (I) and pharmaceutically acceptable carrier or diluting agent. Invention relates also to method of inhibition of activity of human or animal COX-2 involving administration of compound of the formula (I) in effective amount. The claimed compounds can be used for production of medicinal agent. EFFECT: new derivatives of 2-(3H)-oxazolone, valuable medicinal properties. 18 cl, 4 tbl
Patients receive a placebo PO QD for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients will also undergo biopsies and blood collections on study.
Wilson's disease (hepatolenticular degeneration) is an autosomal recessive metabolic defect in hepatic excretion of copper in the bile, resulting in accumulation of excess copper in the liver, and subsequently in other organs, including the brain, kidneys, eyes, bone, and muscles. In this disease, hepatocytes store excess copper, but when their capacity is exceeded copper is released into the blood and is taken up in extrahepatic sites, such as the brain, resulting in motor disorders (ataxia, tremors, speech difficulties) and psychiatric manifestations (irritability, depression, deterioration of work performance). Redistribution of excess copper in hepatocytes leads to hepatocellular injury, inflammation, necrosis, and eventual cirrhosis. Patients may present clinically with predominantly hepatic, neurologic, or psychiatric symptoms.

The disease has been treated by restricting copper in the diet, and the use of chelating agents to bind free copper to reduce its toxicity and facilitate its excretion. The purpose of initial treatment of symptomatic patients with a chelating agent is to detoxify copper. Once the patient's symptoms have stabilized clinically, maintenance treatment begins. Clinical measures are used to determine whether the patient remains stable (See PRECAUTIONS: Monitoring Patients).

The active moiety in zinc acetate is zinc cation. Regardless of the ligand, zinc blocks the intestinal absorption of copper from the diet and the reabsorption of endogenously secreted copper such as that from the saliva, gastric juice and bile. Zinc induces the production of metallothionein in the enterocyte, a protein that binds copper thereby preventing its serosal transfer into the blood. The bound copper is then lost in the stool following desquamation of the intestinal cells.
Multi-condition support program from Welldoc subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter.
PURPOSE: A composition containing inwardly rectifying K+ channel Kir 2.2 inhibitor is provided to suppress cancer cell proliferation and effectively treat cancer. CONSTITUTION: A composition for treating cancer contains a material which suppresses Kir2.2 expression or activation as an active ingredient. The Kir2.2 protein has an amino acid of sequence number 1 or 2. The material is an antisense oligonucleotide of Kir2.2, siRNA(small interfering RNA), or shRNA(small hairpin RNA). The material is a monoclonal antibody or polyclonal antibody specifically suppressing activation of Kir2.2 protein. A method for diagnosing cancer comprises: a step of measuring expression level or activation level of Kir2.2 protein in cell sample; and a step of comparing expression or activation level of Kir2.2 protein between control group and the experimental group.
Placebo Korean red ginseng capsule contain cornstarch powder with the same color and taste as Korean red ginseng. Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
This is a randomized, open-label, comparative study of CAELYX versus Paclitaxel HCl in the treatment of patients with epithelial ovarian carcinoma following failure of first line chemotherapy with a platinum-based regimen. Patients entering the trial will be stratified prospectively for platinum-sensitivity and bulky disease and analyzed retrospectively for prior anthracycline therapy. Protocol-eligible patients, with measurable disease, who have received no more than one prior regimen, which was platinum-based, will be randomized to receive either a one-hour intravenous infusion of CAELYX, 50 mg/m2 every 28 days, or Paclitaxel HCl, 175 mg/m2 as a 3 hour infusion every 21 days. Patients will be treated for up to one year. It is suggested that responding patients receive at least 6 cycles of treatment. Patients with ongoing clinical benefit may continue study drug upon approval of the sponsor as long as it is in the patient's interest and in the absence of severe toxicity. It is suggested that patients exhibiting a complete response (CR) receive 2 subsequent cycles of treatment. Patients exhibiting partial response (PR) may continue to receive study drug as long as therapeutic benefit is being derived but it is suggested that they receive at least 3 subsequent cycles of study drug. Patients will undergo appropriate radiological imaging (x-ray, CT scan, MRI) to document baseline disease, as well as a chest x-ray and an assessment of left ventricular ejection fraction (LVEF) by MUGA scan within 30 days prior to the first dose of study drug. Patients will be followed weekly for hematological toxicities. Radiological imaging will be repeated every 7-8 weeks to assess disease status. Patients who achieve complete or partial response will be reevaluated 4 weeks later to confirm the initial observation of response. All patients will be followed for a minimum of one year for disease progression and survival. LVEF will be assessed by MUGA scan at baseline, when the cumulative anthracycline dose reaches 300 mg/m2 (500 mg/m2 epirubicin), and after every 2 cycles of CAELYX thereafter. Endomyocardial biopsy is recommended for patients who have received \> 400 mg/m2 of CAELYX alone or a cumulative anthracycline dose of \> 550 mg/m2 (including CAELYX; 900 mg/m2 if epirubicin). \[NOTE: This study was initiated on 7-May-1997. Due to poor accrual, the study enrollment was terminated on 31-Aug-1999. Patients were followed until study completion on 12-Apr-2000. During the preparation of the study report (beginning in May 2003), the sites were re-queried for clarification of safety and survival data.\]

DOXIL, dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year. Paclitaxel, dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cycle for up to 1 year.
The invention discloses a 1,8 naphthalimide derivative, a preparation method and application thereof. The invention takes 4-bromo-1, 8-naphthalene anhydride as an initial raw material, and carries out nucleophilic substitution reaction with 5-substituted benzotriazole to obtain an intermediate a-c; the intermediates a-c react with 3 different diamine compounds to form naphthalimides, and target products 1a-3c shown in the formula (I) are obtained. Wherein: r is R  1  Hydrogen, fluorine or chlorine; r is R  2  Is dimethylamino, diethanolamino or piperazinyl. All target compounds of the invention evaluate cytotoxicity of different tumor cells through CCK-8 experimental technology, and compound 3a with better activity is used for researching the action of the compound on human B lymphomas-2 protooncogene (Bcl-2) DNA sequence. The compound can well act on a sequence rich in guanine G of human protooncogene Bcl-2Pu39DNA, and can stabilize a Bcl-2G-quadruplex structure. The invention provides a direction for the research and development of clinical medicines for discovering novel antitumor small molecule medicines, in particular to 1,8 naphthalimide derivatives targeted to Bcl-2.
The volunteers included in the study will perform an evaluation to verify the eligibility criteria, physical evaluation (weight, height, systemic blood pressure) and functional capacity to determine the exercise parameters. After will be presented to the four interventions, ie the recovery techniques after the exercises favoring their adaptation. There will be four resistance exercise sessions followed by interventions with a one week interval between each session. Interventions (passive recovery = 1, active recovery = 2, recovery with IAF = 3 and recovery with myofascial self-release = 4) will be randomized. Functionality assessments will be performed before and one hour after the intervention protocol. DOMS will be evaluated 24 and 72 hours after the exercise protocol. Evaluators will be blind to interventions.
BACKGROUND: High blood pressure (BP) in middle-aged and older adults is associated with lower brain volume and cortical thickness assessed with structural magnetic resonance imaging (MRI). However, little evidence is available on young adults. We investigated the associations of high BP with brain volumes and cortical thickness in healthy young adults.
METHODS: This cross-sectional study included 1,095 young adults (54% women, 22-37 years) from the Human Connectome Project (HCP) who self-reported not having a history of hypertension or taking antihypertensive medications. Brachial systolic (SBP) and diastolic BP (DBP) were measured with a semi-automatic or manual sphygmomanometer during study visits. Structural MRI was used to measure gray matter (GM) and white matter (WM) volume and mean cortical thickness. Associations of BP and hypertension stage with total and regional brain volumes and cortical thickness were analyzed using linear regression and analysis of covariance (ANCOVA) after adjusting for age, sex, education years, body mass index (BMI), smoking, alcohol consumption history, zygosity, and total intracranial volume.
RESULTS: SBP and DBP were (mean ± SD) 123.6 ± 14.2 and 76.5 ± 10.6 mm Hg, respectively, (n = 1,095). High DBP was associated with lower total GM (P = 0.012), cortical GM (P = 0.004), subcortical GM (P = 0.012), and total WM volumes (P = 0.031). High SBP and DBP were associated with lower regional cortical volume and cortical thickness.
CONCLUSIONS: These findings suggest that high BP may have deleterious effects on brain health at the early stage of adulthood.
The invention relates to methods of preparing and assessing purified preparations of an RNA comprising a modified nucleoside. Thus, in one embodiment, the invention is a purified preparation of messenger RNA comprising a 1-methylpseudouridine residue. In some embodiments, the messenger RNA also comprises a polyA tail. In some embodiments, the messenger RNA also comprises an m7GpppG cap. In some embodiments, the messenger RNA also comprises a cap-independent translational enhancer. In some embodiments, the messenger RNA comprises at least about 95% to about 99.9% of all the nucleic acid present in the purified preparation. In some embodiments, the purified preparation of messenger RNA is significantly less immunogenic than an unpurified preparation of messenger RNA with the same sequence.
A three-dimensional (3D) model of a person may be obtained using a pre-trained neural network based on one or more images of the person. Such models may be affected by estimation bias and/or other types of defects or errors. Systems, methods, and apparatuses for improving 3D models and/or neural networks for generating 3D models are described herein. The proposed techniques may extract information such as body keypoint locations and/or body shapes from the images and use the extracted information to refine the 3D model and/or the neural network. In an example, the 3D model and/or neural network may be refined by minimizing the difference between the body keypoint locations and/or body shapes extracted from the image and the corresponding body keypoint locations and/or body shapes determined from the 3D model. The refinement may be performed in an iterative and alternating manner.
Take guanfacine extended-release tablets orally once daily, either in the morning or evening, at approximately the same time each day. Begin at a dose of 1 mg/day, and adjust in increments of no more than 1 mg/week.

In monotherapy clinical trials, there was dose- and exposure-related clinical improvement as well as risks for several clinically significant adverse reactions (hypotension, bradycardia, sedative events). To balance the exposure-related potential benefits and risks, the recommended target dose range depending on clinical response and tolerability for guanfacine extended-release tablets is 0.05 to 0.12 mg/kg/day (total daily dose between 1 to 7 mg) (See Table 1). 

In the adjunctive trial which evaluated guanfacine extended-release tablets treatment with psychostimulants, the majority of patients reached optimal doses in the 0.05 to 0.12 mg/kg/day range. Doses above 4 mg/day have not been studied in adjunctive trials.
PROBLEM TO BE SOLVED: To prepare a cosmetic, capable of assuming excellent preventing actions on the senescence and suitably usable for a makeup cosmetic, a bath product, etc., including a basic cosmetic by using a hydrolyzate obtained by carrying out specific treatment of an alkaline extract of processed rice. SOLUTION: This cosmetic for preventing senescence is obtained by treating an alkaline extract of processed rice prepared by previously processing rice according to, e.g. steam heat-treatment, pressurizing treatment or defatting treatment with one or more enzymes and blending the resultant hydrolyzate therein. At least one proteolytic enzyme selected from actinases, pepsins, trypsins, papains, peptidases and bromelains is used as the enzymes for treating the alkaline extract. Furthermore, a solution containing the hydrolyzate is preferably regulated to pH about 4-8 from the viewpoint of safety for the skin. The hydrolyzate is blended in an amount of >=0.0001 pt., preferably 0.001 pt., based on 100 pts. cosmetic for preventing the senescence expressed in terms of the solid content.
A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
Participants who received primary vaccination in study V48P7 on Days 0, 14 (+3) and 300 (+21) (133 participants) and who received a booster vaccination in study V48P7E1 (NCT00387634) (109 participants). For these participants a second booster vaccination within six months after the annual blood draw was to be administered within the present study only in case their NT titer resulted below 10.
NEW MATERIAL:A compound shown by the formula I (R is lower alkoxy, mono- or di-substituted aralkyl, or lower alkyl) and its acid addition salt. EXAMPLE:1,2,3,4,4a,9b-Hexahydro-9-[ 2-hydroxy-3-( 1-methylethylamino )propoxy ]benzo[b]benzofuran. USE:A drug useful for remedying arrhythmia, preventing angina pectoris, remedying hypertension, etc. Having beta-adrenoceptive blocking action. PREPARATION:A compound shown by the formula II is reacted with an epihalohydrin in alkali aqueous solution to give a compound shown by the formula III, and it is then reacted with a primary amine shown by the formula RNH2, to give a compound shown by the formula I . NaOH is preferably used as the alkali. The reaction of the amine is carried out in an inert solvent such as methanol, ethanol, etc. for 30min- several hours under reflux by heating.